Ticker
AADI

Price
12.53
Stock movement up
+- (%)
Company name
Aadi Bioscience Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
305.67M
Ent value
195.85M
Price/Sales
27.82
Price/Book
1.81
Div yield
-
Div growth
-
Growth years
-
FCF payout
-4.62%
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-30.35%
3 year return
-56.87%
5 year return
-59.31%
10 year return
-
Last updated: 2023-02-03

DIVIDENDS

AADI does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales27.82
Price to Book1.81
EV to Sales17.82

FINANCIALS

Per share

Loading...
Per share data
Current share count24.40M
EPS (TTM)-2.94
FCF per share (TTM)-3.84

Income statement

Loading...
Income statement data
Revenue (TTM)10.99M
Gross profit (TTM)10.00M
Operating income (TTM)-63.16M
Net income (TTM)-62.59M
EPS (TTM)-2.94
EPS (1y forward)-2.53

Margins

Loading...
Margins data
Gross margin (TTM)90.96%
Operating margin (TTM)-574.71%
Profit margin (TTM)-569.57%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash134.81M
Net receivables2.26M
Total current assets189.86M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets194.10M
Accounts payable3.92M
Short/Current long term debt1.72M
Total current liabilities17.89M
Total liabilities25.00M
Shareholder's equity169.11M
Net tangible assets169.11M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-80.89M
Capital expenditures (TTM)676.00K
Free cash flow (TTM)-81.57M
Dividends paid (TTM)3.77M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-37.01%
Return on Assets-32.25%
Return on Invested Capital-36.93%
Cash Return on Invested Capital-48.13%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open12.50
Daily high12.74
Daily low12.42
Daily Volume70K
All-time high1485.00
1y analyst estimate41.67
Beta-
EPS (TTM)-2.94
Dividend per share-
Ex-div date-
Next earnings date15 Mar 2023

Downside potential

Loading...
Downside potential data
AADIS&P500
Current price drop from All-time high-99.16%-13.68%
Highest price drop-99.22%-56.47%
Date of highest drop11 May 20229 Mar 2009
Avg drop from high-75.72%-11.49%
Avg time to new high70 days13 days
Max time to new high1305 days1805 days
COMPANY DETAILS
AADI (Aadi Bioscience Inc) company logo
Marketcap
305.67M
Marketcap category
Small-cap
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Employees
76
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTO...
November 17, 2022
Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, ...
November 9, 2022
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announce...
November 8, 2022
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTO...
November 3, 2022
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTO...
October 27, 2022
Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc. (Nasdaq: AADI), a commercial stage biopharmaceutical company focused on developing and c...
October 12, 2022
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announce...
September 22, 2022
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTO...
September 1, 2022
Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, ...
August 10, 2022
Every investor in Aadi Bioscience, Inc. ( NASDAQ:AADI ) should be aware of the most powerful shareholder groups...
August 4, 2022
Next page